Biosimilars, Legal

Pfizer’s latest copycat could put the squeeze on Roche — again

Pfizer $PFE is barreling forward on its plans to recreate Roche’s stalwart cancer drugs, announcing positive data this morning for its Rituxan copycat called PF-05280586. Considering Roche’s $RHHBY recent backlash to biosimilar competition, it’s possible that Pfizer will continue to poke the rather litigious bear.

Like you’d want to see from a biosimilar, PF-05280586’s trial met its primary endpoint and showed equivalence in overall response rate for patients with CD20-positive follicular lymphoma.

Amrit Ray

“These results reinforce the potential of our proposed rituximab biosimilar in providing a safe and effective treatment option for patients,” said Pfizer’s R&D president Amrit Ray in a statement.

Considering its loss of patent protections for core brands like Lipitor and Viagra, investing in biosimilars is a growth strategy for Pfizer. Biosimilars, a purported $10 billion to $30 billion global market opportunity, is the company’s new target.

Years ago, Pfizer got FDA approval for Inflectra, its knockoff of J&J’s Remicade. Now it’s taking on Roche’s cancer portfolio: Herceptin, Avastin, and Rituxan. That’s largely due to the company’s 2015 acquisition of Hospira, which was developing biosimilars for those drugs. US sales for these biologics was around $9.5 billion in 2016. Since copycats are priced 20% under, some have speculated that Pfizer is looking at a $7.5 billion addressable market.

But as Pfizer puts the squeeze on Roche and J&J’s revenue, these drugmakers are fighting back.

Roche launched a legal battle against Pfizer for its Herceptin copycat, alleging Pfizer had infringed on 40 of Roche’s patents. The backlash makes sense. Herceptin sales makes up a big chunk of the Roches’s total revenue, bringing in about $2.5 billion in sales last year (or 5% of total revenue).

J&J, on the other hand, has made deep cost cuts to Remicade to keep Pfizer’s rival biosimilar at bay. Pfizer sued J&J alleging the company was using “exclusionary contracts” that barred Pfizer from reaching most patients. Pfizer got some good news on that battle front earlier this week, as a US appeals court upheld a ruling that invalidated a key patent for Remicade.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 31,500+ biopharma pros who read Endpoints News by email every day.

Free Subscription


Chief Medical Officer
Skyhawk Therapeutics Waltham, MA
Chief of Staff, North America
Ipsen Biopharmaceuticals Cambridge, MA
Senior Director, NA Digital Customer Interaction
Ipsen Biopharmaceuticals Cambridge, MA
GMP Supervisor - Downstream
Molecular Templates Austin, TX
Quality Control (QC) Associate
Molecular Templates Austin, TX

Visit Endpoints Careers ->